The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Regulation and Role of EZH2 in Cancer
Open accessAbstract
Polycomb repressive complex 2 (PRC2) is the epigenetic regulator that induces histone H3 lysine 27 methylation (H3K27me3) and silences specific gene transcription. Enhancer of zeste homolog 2 (EZH2) is an enzymatic subunit of PRC2, and evidence shows that EZH2 plays an essential role in cancer initiation, development, progression, metastasis, and drug resistance. EZH2 expression is indeed regulated by various oncogenic transcription factors, tumor suppressor miRNAs, and cancer-associated non-coding RNA. EZH2 activity is also controlled by post-translational modifications, which are deregulated in cancer. The canonical role of EZH2 is gene silencing through H3K27me3, but accumulating evidence shows that EZH2 methlyates substrates other than histone and has methylase-independent functions. These non-canonical functions of EZH2 are shown to play a role in cancer progression. In this review, we summarize current information on the regulation and roles of EZH2 in cancer. We also discuss various therapeutic approaches to targeting EZH2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Retracted: Role of STAT3 and vitamin D receptor in EZH2‐mediated invasion of human colorectal cancer
Lin, Y., Ren, L., Xiong, H., Du, W., Yu, Y., Sun, T., Weng, Y., Wang, Z., Wang, J., Wang, Y., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4179 · Cited by 42
RetractedLong non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M.-C., Hung, T., Argani, P., Rinn, J. L., et al. (2010) · Nature · doi:10.1038/nature08975 · Cited by 5,218
Long Noncoding RNA as Modular Scaffold of Histone Modification Complexes
Tsai, M.-C., Manor, O., Wan, Y., Mosammaparast, N., Wang, J. K., Lan, F., Shi, Y., Segal, E., & Chang, H. Y. (2010) · Science · doi:10.1126/science.1192002 · Cited by 3,290 · cited 1×
“Remarkably, HOTAIR can interact with PRC2 and the LSD1/CoREST/REST repressor complex (which is responsible for the demethylation of H3K4me2), serving as a scaffold to recruit two distinct histone modifiers to the same loci [56].”
BackgroundEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Polycomb Proteins Targeted by a Short Repeat RNA to the Mouse X Chromosome
Zhao, J., Sun, B. K., Erwin, J. A., Song, J.-J., & Lee, J. T. (2008) · Science · doi:10.1126/science.1163045 · Cited by 1,579
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D. (2013) · Science · doi:10.1126/science.1232245 · Cited by 1,345
Mechanisms of Polycomb gene silencing: knowns and unknowns
Simon, J. A., & Kingston, R. E. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2763 · Cited by 1,317
Kogo, R., Shimamura, T., Mimori, K., Kawahara, K., Imoto, S., Sudo, T., Tanaka, F., Shibata, K., Suzuki, A., Komune, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1021 · Cited by 1,238
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052
Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., Laxman, B., Asangani, I. A., Grasso, C. S., Kominsky, H. D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1914 · Cited by 1,029
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
Bachmann, I. M., Halvorsen, O. J., Collett, K., Stefansson, I. M., Straume, O., Haukaas, S. A., Salvesen, H. B., Otte, A. P., & Akslen, L. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5180 · Cited by 851
Bracken, A. P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Mönch, K., Minucci, S., Porse, B. T., Marine, J.-C., et al. (2007) · Genes & Development · doi:10.1101/gad.415507 · Cited by 850
Béguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang, S. N., Wang, L., Ezponda, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.011 · Cited by 846
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T. W., Kool, M., Zapatka, M., Northcott, P. A., Sturm, D., Wang, W., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.006 · Cited by 818
Kim, E., Kim, M., Woo, D.-H., Shin, Y., Shin, J., Chang, N., Oh, Y. T., Kim, H., Rheey, J., Nakano, I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.008 · Cited by 806
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer
Kim, K., Jutooru, I., Chadalapaka, G., Johnson, G., Frank, J., Burghardt, R., Kim, S., & Safe, S. (2013) · Oncogene · doi:10.1038/onc.2012.193 · Cited by 782
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E. R. L. T. M., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 755
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Chan, K.-M., Fang, D., Gan, H., Hashizume, R., Yu, C., Schroeder, M., Gupta, N., Mueller, S., James, C. D., Jenkins, R., et al. (2013) · Genes & Development · doi:10.1101/gad.217778.113 · Cited by 707
MicroRNA-directed transcriptional gene silencing in mammalian cells
Kim, D. H., Sætrom, P., Snøve, O., & Rossi, J. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808830105 · Cited by 705
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 683
Yang, F., Zhang, L., Huo, X.-S., Yuan, J.-H., Xu, D., Yuan, S.-X., Zhu, N., Zhou, W.-P., Yang, G.-S., Wang, Y.-Z., et al. (2011) · Hepatology · doi:10.1002/hep.24563 · Cited by 632
Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells
Ezhkova, E., Pasolli, H. A., Parker, J. S., Stokes, N., Su, I.-H., Hannon, G., Tarakhovsky, A., & Fuchs, E. (2009) · Cell · doi:10.1016/j.cell.2008.12.043 · Cited by 604
Caretti, G., Di Padova, M., Micales, B., Lyons, G. E., & Sartorelli, V. (2004) · Genes & Development · doi:10.1101/gad.1241904 · Cited by 600
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R.-S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., Yu, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.333 · Cited by 583
Luo, M., Li, Z., Wang, W., Zeng, Y., Liu, Z., & Qiu, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.033 · Cited by 549
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3
Cha, T.-L., Zhou, B. P., Xia, W., Wu, Y., Yang, C.-C., Chen, C.-T., Ping, B., Otte, A. P., & Hung, M.-C. (2005) · Science · doi:10.1126/science.1118947 · Cited by 548
Self-citationSelective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 547
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Ntziachristos, P., Tsirigos, A., Vlierberghe, P. V., Nedjic, J., Trimarchi, T., Flaherty, M. S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2651 · Cited by 526
Knutson, S. K., Kawano, S., Minoshima, Y., Warholic, N. M., Huang, K.-C., Xiao, Y., Kadowaki, T., Uesugi, M., Kuznetsov, G., Kumar, N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0773 · Cited by 523
Tiwari, N., Tiwari, V. K., Waldmeier, L., Balwierz, P. J., Arnold, P., Pachkov, M., Meyer-Schaller, N., Schübeler, D., van Nimwegen, E., & Christofori, G. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.020 · Cited by 484
McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 483
EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
Suvà, M.-L., Riggi, N., Janiszewska, M., Radovanovic, I., Provero, P., Stehle, J.-C., Baumer, K., Le Bitoux, M.-A., Marino, D., Cironi, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1622 · Cited by 465
Lee, J., Son, M. J., Woolard, K., Donin, N. M., Li, A., Cheng, C. H., Kotliarova, S., Kotliarov, Y., Walling, J., Ahn, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.005 · Cited by 429
Chang, C.-J., Yang, J.-Y., Xia, W., Chen, C.-T., Xie, X., Chao, C.-H., Woodward, W. A., Hsu, J.-M., Hortobagyi, G. N., & Hung, M.-C. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.035 · Cited by 408
Self-citationContext-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers
Lee, S. T., Li, Z., Wu, Z., Aau, M., Guan, P., Karuturi, R. K. M., Liou, Y. C., & Yu, Q. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.011 · Cited by 399
Regulation of Tumor Angiogenesis by EZH2
Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., Armaiz-Pena, G. N., Hu, W., Stone, R. L., Munkarah, A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.016 · Cited by 399
Self-citationKaneko, S., Li, G., Son, J., Xu, C.-F., Margueron, R., Neubert, T. A., & Reinberg, D. (2010) · Genes & Development · doi:10.1101/gad.1983810 · Cited by 398
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F. E., Möller, P., Stilgenbauer, S., Pollack, J. R., & Wirth, T. (2008) · Blood · doi:10.1182/blood-2008-03-147645 · Cited by 395
Palacios, D., Mozzetta, C., Consalvi, S., Caretti, G., Saccone, V., Proserpio, V., Marquez, V. E., Valente, S., Mai, A., Forcales, S. V., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.013 · Cited by 392
Wei, Y., Chen, Y.-H., Li, L.-Y., Lang, J., Yeh, S.-P., Shi, B., Yang, C.-C., Yang, J.-Y., Lin, C.-Y., Lai, C.-C., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2139 · Cited by 384
Self-citationFriedman, J. M., Liang, G., Liu, C.-C., Wolff, E. M., Tsai, Y. C., Ye, W., Zhou, X., & Jones, P. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3114 · Cited by 382
Lu, J., He, M.-L., Wang, L., Chen, Y., Liu, X., Dong, Q., Chen, Y.-C., Peng, Y., Yao, K.-T., Kung, H.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1850 · Cited by 381
Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S. K., Reczek, E. E., De Raedt, T., Guney, I., Strochlic, D. E., MacConaill, L. E., Beroukhim, R., et al. (2010) · Nature Medicine · doi:10.1038/nm.2100 · Cited by 380
Polycomb group protein-mediated repression of transcription
Morey, L., & Helin, K. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.02.009 · Cited by 380
Zheng, F., Liao, Y.-J., Cai, M.-Y., Liu, Y.-H., Liu, T.-H., Chen, S.-P., Bian, X.-W., Guan, X.-Y., Lin, M. C., Zeng, Y.-X., et al. (2012) · Gut · doi:10.1136/gut.2011.239145 · Cited by 376
Interactions between JARID2 and Noncoding RNAs Regulate PRC2 Recruitment to Chromatin
Kaneko, S., Bonasio, R., Saldaña-Meyer, R., Yoshida, T., Son, J., Nishino, K., Umezawa, A., & Reinberg, D. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.012 · Cited by 371
Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling
Su, I.-H., Dobenecker, M.-W., Dickinson, E., Oser, M., Basavaraj, A., Marqueron, R., Viale, A., Reinberg, D., Wülfing, C., & Tarakhovsky, A. (2005) · Cell · doi:10.1016/j.cell.2005.02.029 · Cited by 365
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2
Shen, J., Xia, W., Khotskaya, Y. B., Huo, L., Nakanishi, K., Lim, S.-O., Du, Y., Wang, Y., Chang, W.-C., Chen, C.-H., et al. (2013) · Nature · doi:10.1038/nature12080 · Cited by 356
Self-citationShi, B., Liang, J., Yang, X., Wang, Y., Zhao, Y., Wu, H., Sun, L., Zhang, Y., Chen, Y., Li, R., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00162-07 · Cited by 340
Liu, Z., Sun, M., Lu, K., Liu, J., Zhang, M., Wu, W., De, W., Wang, Z., & Wang, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077293 · Cited by 309
Richter, G. H. S., Plehm, S., Fasan, A., Rössler, S., Unland, R., Bennani-Baiti, I. M., Hotfilder, M., Löwel, D., von Luettichau, I., Mossbrugger, I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810759106 · Cited by 305
Bao, B., Ali, S., Banerjee, S., Wang, Z., Logna, F., Azmi, A. S., Kong, D., Ahmad, A., Li, Y., Padhye, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2182 · Cited by 297
PRC2 directly methylates GATA4 and represses its transcriptional activity
He, A., Shen, X., Ma, Q., Cao, J., von Gise, A., Zhou, P., Wang, G., Marquez, V. E., Orkin, S. H., & Pu, W. T. (2012) · Genes & Development · doi:10.1101/gad.173930.111 · Cited by 291
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2
Chen, S., Bohrer, L. R., Rai, A. N., Pan, Y., Gan, L., Zhou, X., Bagchi, A., Simon, J. A., & Huang, H. (2010) · Nature Cell Biology · doi:10.1038/ncb2116 · Cited by 281
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Simon, C., Chagraoui, J., Krosl, J., Gendron, P., Wilhelm, B., Lemieux, S., Boucher, G., Chagnon, P., Drouin, S., Lambert, R., et al. (2012) · Genes & Development · doi:10.1101/gad.186411.111 · Cited by 264
Jarid2 Is Implicated in the Initial Xist-Induced Targeting of PRC2 to the Inactive X Chromosome
da Rocha, S. T., Boeva, V., Escamilla-Del-Arenal, M., Ancelin, K., Granier, C., Matias, N. R., Sanulli, S., Chow, J., Schulz, E., Picard, C., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.01.002 · Cited by 263
EZH2 Generates a Methyl Degron that Is Recognized by the DCAF1/DDB1/CUL4 E3 Ubiquitin Ligase Complex
Lee, J. M., Lee, J. S., Kim, H., Kim, K., Park, H., Kim, J.-Y., Lee, S. H., Kim, I. S., Kim, J., Lee, M., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.004 · Cited by 247
Zhu, L., & Xu, P.-C. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.036 · Cited by 242
MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion
Wang, H.-J., Ruan, H.-J., He, X.-J., Ma, Y.-Y., Jiang, X.-T., Xia, Y.-J., Ye, Z.-Y., & Tao, H.-Q. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.012 · Cited by 240
Smits, M., Nilsson, J., Mir, S. E., van der Stoop, P. M., Hulleman, E., Niers, J. M., de Witt Hamer, P. C., Marquez, V. E., Cloos, J., Krichevsky, A. M., et al. (2010) · Oncotarget · doi:10.18632/oncotarget.205 · Cited by 236
O-GlcNAcylation regulates EZH2 protein stability and function
Chu, C.-S., Lo, P.-W., Yeh, Y.-H., Hsu, P.-H., Peng, S.-H., Teng, Y.-C., Kang, M.-L., Wong, C.-H., & Juan, L.-J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323226111 · Cited by 231
Zhang, B., Liu, X.-X., He, J.-R., Zhou, C.-X., Guo, M., He, M., Li, M.-F., Chen, G.-Q., & Zhao, Q. (2011) · Carcinogenesis · doi:10.1093/carcin/bgq209 · Cited by 228
Kong, D., Heath, E., Chen, W., Cher, M. L., Powell, I., Heilbrun, L., Li, Y., Ali, S., Sethi, S., Hassan, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033729 · Cited by 219
Matsukawa, Y., Semba, S., Kato, H., Ito, A., Yanagihara, K., & Yokozaki, H. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00203.x · Cited by 212
Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis
Ciavatta, D. J., Yang, J., Preston, G. A., Badhwar, A. K., Xiao, H., Hewins, P., Nester, C. M., Pendergraft, W. F., Magnuson, T. R., Jennette, J. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40034 · Cited by 210
Tong, Z.-T., Cai, M.-Y., Wang, X.-G., Kong, L.-L., Mai, S.-J., Liu, Y.-H., Zhang, H.-B., Liao, Y.-J., Zheng, F., Zhu, W., et al. (2012) · Oncogene · doi:10.1038/onc.2011.254 · Cited by 210
Cheng, A. S. L., Lau, S. S., Chen, Y., Kondo, Y., Li, M. S., Feng, H., Ching, A. K., Cheung, K. F., Wong, H. K., Tong, J. H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3342 · Cited by 208
Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer
Cao, Q., Mani, R.-S., Ateeq, B., Dhanasekaran, S. M., Asangani, I. A., Prensner, J. R., Kim, J. H., Brenner, J. C., Jing, X., Cao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.016 · Cited by 204
Kondo, Y., Shen, L., Suzuki, S., Kurokawa, T., Masuko, K., Tanaka, Y., Kato, H., Mizuno, Y., Yokoe, M., Sugauchi, F., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00141.x · Cited by 203
Gonzalez, M. E., Li, X., Toy, K., DuPrie, M., Ventura, A. C., Banerjee, M., Ljungman, M., Merajver, S. D., & Kleer, C. G. (2009) · Oncogene · doi:10.1038/onc.2008.433 · Cited by 195
Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation
Fujii, S., Ito, K., Ito, Y., & Ochiai, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800224200 · Cited by 193
Ougolkov, A. V., Bilim, V. N., & Billadeau, D. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1013 · Cited by 193
Increased Expression of the Polycomb Group Gene, EZH2, in Transitional Cell Carcinoma of the Bladder
Raman, J. D., Mongan, N. P., Tickoo, S. K., Boorjian, S. A., Scherr, D. S., & Gudas, L. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1047 · Cited by 193
EZH2 expands breast stem cells through activation of NOTCH1 signaling
Gonzalez, M. E., Moore, H. M., Li, X., Toy, K. A., Huang, W., Sabel, M. S., Kidwell, K. M., & Kleer, C. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308953111 · Cited by 188
PAF and EZH2 Induce Wnt/β-Catenin Signaling Hyperactivation
Jung, H.-Y., Jun, S., Lee, M., Kim, H.-C., Wang, X., Ji, H., McCrea, P. D., & Park, J.-I. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.028 · Cited by 184
Intronic RNAs mediate EZH2 regulation of epigenetic targets
Guil, S., Soler, M., Portela, A., Carrère, J., Fonalleras, E., Gómez, A., Villanueva, A., & Esteller, M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2315 · Cited by 181
MicroRNA-138 suppresses epithelial–mesenchymal transition in squamous cell carcinoma cell lines
Liu, X., Wang, C., Chen, Z., Jin, Y., Wang, Y., Kolokythas, A., Dai, Y., & Zhou, X. (2011) · Biochemical Journal · doi:10.1042/bj20111006 · Cited by 181
Koh, C. M., Iwata, T., Zheng, Q., Bethel, C., Yegnasubramanian, S., & De Marzo, A. M. (2011) · Oncotarget · doi:10.18632/oncotarget.327 · Cited by 180
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders
Muto, T., Sashida, G., Oshima, M., Wendt, G. R., Mochizuki-Kashio, M., Nagata, Y., Sanada, M., Miyagi, S., Saraya, A., Kamio, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131144 · Cited by 178
EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia
Li, J., Hart, R. P., Mallimo, E. M., Swerdel, M. R., Kusnecov, A. W., & Herrup, K. (2013) · Nature Neuroscience · doi:10.1038/nn.3564 · Cited by 176
EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ1 , CLU , RUNX3 , and NGFR
Wang, C., Liu, Z., Woo, C.-W., Li, Z., Wang, L., Wei, J. S., Marquez, V. E., Bates, S. E., Jin, Q., Khan, J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-0961 · Cited by 175
Zhang, J.-G., Guo, J.-F., Liu, D.-L., Liu, Q., & Wang, J.-J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318208eb35 · Cited by 173
Crea, F., Hurt, E. M., Mathews, L. A., Cabarcas, S. M., Sun, L., Marquez, V. E., Danesi, R., & Farrar, W. L. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-40 · Cited by 173
Kalashnikova, E. V., Revenko, A. S., Gemo, A. T., Andrews, N. P., Tepper, C. G., Zou, J. X., Cardiff, R. D., Borowsky, A. D., & Chen, H.-W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1199 · Cited by 168
Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
Asangani, I. A., Ateeq, B., Cao, Q., Dodson, L. M., Pandhi, M. B., Kunju, L. P., Mehra, R., Lonigro, R. J., Siddiqui, J., Palanisamy, N., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.10.008 · Cited by 166
Xia, H., Ooi, L. L. P. J., & Hui, K. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044206 · Cited by 164
Yan, J., Ng, S.-B., Tay, J. L.-S., Lin, B., Koh, T. L., Tan, J., Selvarajan, V., Liu, S.-C., Bi, C., Wang, S., et al. (2013) · Blood · doi:10.1182/blood-2012-08-450494 · Cited by 164
Yang, X., Karuturi, R. K. M., Sun, F., Aau, M., Yu, K., Shao, R., Miller, L. D., Tan, P. B. O., & Yu, Q. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005011 · Cited by 164
Chen, Y., Lin, M. C., Yao, H., Wang, H., Zhang, A.-Q., Yu, J., Hui, C.-K., Lau, G. K., He, M.-L., Sung, J., et al. (2007) · Hepatology · doi:10.1002/hep.21668 · Cited by 163
Alajez, N. M., Shi, W., Hui, A. B. Y., Bruce, J., Lenarduzzi, M., Ito, E., Yue, S., O'Sullivan, B., & Liu, F.-F. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.64 · Cited by 160
Hwang-Verslues, W. W., Chang, P.-H., Jeng, Y.-M., Kuo, W.-H., Chiang, P.-H., Chang, Y.-C., Hsieh, T.-H., Su, F.-Y., Lin, L.-C., Abbondante, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222684110 · Cited by 159
Hu, S., Yu, L., Li, Z., Shen, Y., Wang, J., Cai, J., Xiao, L., & Wang, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.8.12913 · Cited by 159
Wang, L., Zhang, X., Jia, L.-T., Hu, S.-J., Zhao, J., Yang, J.-D., Wen, W.-H., Wang, Z., Wang, T., Zhao, J., et al. (2014) · Hepatology · doi:10.1002/hep.26720 · Cited by 158
Rapicavoli, N. A., Poth, E. M., Zhu, H., & Blackshaw, S. (2011) · Neural Development · doi:10.1186/1749-8104-6-32 · Cited by 155
Behrens, C., Solis, L. M., Lin, H. Y., Yuan, P., Tang, X., Kadara, H. N., Riquelme, E. M., Galindo, H., Moran, C. A., Kalhor, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3946 · Cited by 155
A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients
Majer, C. R., Jin, L., Scott, M. P., Knutson, S. K., Kuntz, K. W., Keilhack, H., Smith, J. J., Moyer, M. P., Richon, V. M., Copeland, R. A., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.066 · Cited by 154
Guo, Y., Liang, Y. J., Tian, Y., Yang, P., Zhu, Y., Wang, Z., Qiu, F., & Lin, J. (2013) · FEBS Journal · doi:10.1111/febs.12417 · Cited by 154
Luo, C., Tetteh, P. W., Merz, P., Dickes, E., Abukiwan, A., Hotz‐Wagenblatt, A., Holland-Cunz, S. G., Sinnberg, T. W., Schittek, B., Schadendorf, D., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.357 · Cited by 153
Rao, Z.-Y., Cai, M.-Y., Yang, G.-F., He, L.-R., Mai, S., Hua, W., Liao, Y.-J., Deng, H.-X., Chen, Y., Guan, X., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq150 · Cited by 152
Wu, S. C., & Zhang, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.240515 · Cited by 150
Polycomb repressive complex 2 contributes to DNA double-strand break repair
Campbell, S., Ismail, I. H., Young, L. C., Poirier, G. G., & Hendzel, M. J. (2013) · Cell Cycle · doi:10.4161/cc.25795 · Cited by 150
EZH2 couples pancreatic regeneration to neoplastic progression
Clair, J. M., Soydaner-Azeloglu, R. G., Lee, K. E., Taylor, L. J., Livanos, A. E., Pylayeva‐Gupta, Y., Miller, G., Margueron, R., Reinberg, D., & Bar‐Sagi, D. (2012) · Genes & Development · doi:10.1101/gad.181800.111 · Cited by 147
Kunderfranco, P., Mello-Grand, M., Cangemi, R., Pellini, S., Mensah, A., Albertini, V., Malek, A., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010547 · Cited by 143
MiR-138 Inhibits Tumor Growth Through Repression of EZH2 in Non-Small Cell Lung Cancer
Zhang, H., Zhang, H., Zhao, M., Lv, Z., Zhang, X., Qin, X., Wang, H., Wang, S., Su, J., Lv, X., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000343349 · Cited by 143
Reynolds, P. A., Sigaroudinia, M., Zardo, G., Wilson, M. B., Benton, G. M., Miller, C. J., Hong, C., Fridlyand, J., Costello, J., & Tlsty, T. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604175200 · Cited by 137
MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes
Fujii, S., Tokita, K., Wada, N., Ito, K., Yamauchi, C., Ito, Y., & Ochiai, A. (2011) · Oncogene · doi:10.1038/onc.2011.118 · Cited by 137
Fujii, S., & Ochiai, A. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00743.x · Cited by 136
Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells
Dimri, M., Bommi, P. V., Sahasrabuddhe, A. A., Khandekar, J. D., & Dimri, G. P. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp305 · Cited by 133
Wu, Z., Zheng, S., Li, Z. M., Qiao, Y., Aau, M. Y., & Yu, Q. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.162 · Cited by 132
Li, X., González, M. E., Toy, K. A., Filzen, T. M., Merajver, S. D., & Kleer, C. G. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090042 · Cited by 130
Shin, Y. J., & Kim, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030393 · Cited by 128
Cakouros, D., Isenmann, S., Cooper, L., Zannettino, A. C. W., Anderson, P. J., Glackin, C. A., & Gronthos, S. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06315-11 · Cited by 126
He, W., Cai, Q., Sun, F., Zhong, G., Wang, P., Liu, H., Luo, J., Yu, H., Huang, J., & Lin, T. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.010 · Cited by 120
Hua, W., Fu, Y.-S., Liao, Y.-J., Xia, W.-J., Chen, Y., Zeng, Y.-X., Kung, H., & Xie, D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.03.051 · Cited by 119
Hayden, A. L., Johnson, P., Packham, G., & Crabb, S. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0982-0 · Cited by 118
Salvatori, B., Iosue, I., Damas, N. D., Mangiavacchi, A., Chiaretti, S., Messina, M., Padula, F., Guarini, A. R., Bozzoni, I., Fazi, F., et al. (2011) · Genes & Cancer · doi:10.1177/1947601911416357 · Cited by 118
Puppe, J., Drost, R., Liu, X., Joosse, S. A., Evers, B., Cornelissen‐Steijger, P., Nederlof, P. M., Yu, Q., Jonkers, J., van Lohuizen, M., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2354 · Cited by 117
Esposito, F., Tornincasa, M., Pallante, P., Federico, A., Borbone, E., Pierantoni, G. M., & Fusco, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3068 · Cited by 117
The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells
Zeidler, M. G., Varambally, S., Cao, Q., Chinnaiyan, A. M., Ferguson, D. O., Merajver, S. D., & Kleer, C. G. (2005) · Neoplasia · doi:10.1593/neo.05472 · Cited by 115
BRCA1 is a negative modulator of the PRC2 complex
Wang, L., Zeng, X., Chen, S., Ding, L., Zhong, J., Zhao, J. C., Wang, L., Sarver, A. L., Koller, A. A., Zhi, J., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.95 · Cited by 114
Huang, S., Yuan, Y., Zhuang, C.-W., Li, B., Gong, D., Wang, S.-G., Zeng, Z., & Cheng, H.-Z. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-51 · Cited by 114
Banerjee, R., Mani, R. S., Russo, N., Scanlon, C. S., Tsodikov, A., Jing, X., Cao, Q., Palanisamy, N., Metwally, T., Inglehart, R. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.141 · Cited by 113
Gonzalez, M. E., DuPrie, M. L., Krueger, H., Merajver, S. D., Ventura, A. C., Toy, K. A., & Kleer, C. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1933 · Cited by 112
Inner workings and regulatory inputs that control Polycomb repressive complex 2
O’Meara, M., & Simon, J. A. (2012) · Chromosoma · doi:10.1007/s00412-012-0361-1 · Cited by 111
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer
Taniguchi, H., Jacinto, F. V., Villanueva, A., Fernández, A. F., Yamamoto, H., Carmona, F. J., Puertas, S., Márquez, V. E., Shinomura, Y., Imai, K., et al. (2011) · Oncogene · doi:10.1038/onc.2011.387 · Cited by 110
Sasaki, M., Yamaguchi, J., Itatsu, K., Ikeda, H., & Nakanuma, Y. (2008) · The Journal of Pathology · doi:10.1002/path.2345 · Cited by 108
Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Kemp, C. D., Rao, M., Xi, S., Inchauste, S. M., Mani, H., Fetsch, P. A., Filie, A. C., Zhang, M. F., Hong, J. A., Walker, R. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0962 · Cited by 108
Li, Q., Su, Z., Xu, X., Liu, G., Song, X., Wang, R., Sui, X., Liu, T., Chang, X., & Huang, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116597109 · Cited by 106
Yu, Y., Chou, R., Shyu, W., Hsieh, S., Wu, C.-S., Chiang, S., Chang, W., Chen, J., Tseng, Y.-J., Lin, Y.-H., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201783 · Cited by 106
Self-citationAvan, A., Crea, F., Paolicchi, E., Funel, N., Galvani, E., Márquez, V. E., Honeywell, R. J., Danesi, R., Peters, G. J., & Giovannetti, E. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0037 · Cited by 102
Polycomb Target Genes Are Silenced in Multiple Myeloma
Kalushkova, A., Fryknäs, M., Lemaire, M., Fristedt, C., Agarwal, P., Eriksson, M., Deleu, S., Atadja, P. W., Österborg, A., Nilsson, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011483 · Cited by 97
Wang, C., Liu, X., Chen, Z., Huang, H., Jin, Y., Kolokythas, A., Wang, A., Dai, Y. D., Wong, D. T., & Zhou, X. C. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21848 · Cited by 95
Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma
Corvetta, D., Chayka, O., Gherardi, S., D’Acunto, C. W., Cantilena, S., Valli, E., Piotrowska, I., Perini, G., & Sala, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.454280 · Cited by 92
FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells
Du, J., Li, L., Ou, Z., Kong, C., Zhang, Y., Dong, Z., Zhu, S., Jiang, H., Shao, Z., Huang, B., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1396-3 · Cited by 92
A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma
Yang, Y., Zhou, L., Lu, L., Wang, L., Li, X., Jiang, P., Chan, L. K. Y., Zhang, T., Yu, J. Q., Kwong, J., et al. (2012) · Oncogene · doi:10.1038/onc.2012.360 · Cited by 87
Targeting the enhancer of zeste homologue 2 in medulloblastoma
Alimova, I. N., Venkataraman, S., Harris, P. S., Márquez, V. E., Northcott, P. A., Dubuc, A. M., Taylor, M. D., Foreman, N. K., & Vibhakar, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27455 · Cited by 87
Qiu, S., Huang, D., Yin, D., Li, F., Li, X., Kung, H.-F., & Peng, Y. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.015 · Cited by 87
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer
Yu, J., Cao, Q., Yu, J., Wu, L., Dallol, A., Li, J., Chen, G., Grasso, C. S., Cao, X., Lonigro, R. J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.269 · Cited by 85
Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer
Pathiraja, T. N., Nayak, S. R., Xi, Y., Jiang, S., Garee, J. P., Edwards, D. P., Lee, A. V., Chen, J., Shea, M. J., Santen, R. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008326 · Cited by 78
Zhang, H., Niu, B., Hu, J., Ge, S., Wang, H., Li, T., Ling, J., Steelman, B. N., Qian, G., & Hoffman, A. R. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201101021 · Cited by 76
Guo, J., Cai, J., Yu, L., Tang, H., Chen, C., & Wang, Z. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01836.x · Cited by 72
Clinical significance of Polycomb gene expression in brain tumors
Crea, F., Hurt, E. M., & Farrar, W. L. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-265 · Cited by 70
Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells
Sun, F., Chan, E., Wu, Z., Yang, X., Márquez, V. E., & Yu, Q. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0479 · Cited by 69
The Polycomb Repressive Complex 2 Is a Potential Target of SUMO Modifications
Riising, E. M., Boggio, R., Chiocca, S., Helin, K., & Pasini, D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002704 · Cited by 68
Alford, S. H., Toy, K. A., Merajver, S. D., & Kleer, C. G. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1591-2 · Cited by 66
Ochiai (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.868 · Cited by 62
CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor
Wu, L., Runkle, C., Jin, H.-J., Yu, J., Li, J., Yang, X. J., Kuzel, T. M., Lee, C., & Yu, J. (2013) · Oncogene · doi:10.1038/onc.2012.602 · Cited by 62
Garipov, A., Li, H., Bitler, B. G., Thapa, R. J., Balachandran, S., & Zhang, R. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0661 · Cited by 62
Gannon, O. M., de Long, L. M., Endo‐Munoz, L., Hazar-Rethinam, M. H., & Saunders, N. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2505 · Cited by 62
Fujiwara, T., Saitoh, H., Inoue, A., Kobayashi, M., Okitsu, Y., Katsuoka, Y., Fukuhara, N., Onishi, Y., Ishizawa, K., Ichinohasama, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548651 · Cited by 59
Yu, H., Simons, D. L., Segall, I., Cárcamo‐Cavazos, V., Schwartz, E., Yan, N., Zuckerman, N. S., Dirbas, F. M., Johnson, D. L., Holmes, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051239 · Cited by 59
Boulay, G., Dubuissez, M., Rechem, C. V., Forget, A., Helin, K., Ayrault, O., & Leprince, D. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.320234 · Cited by 56
PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins
Zoabi, M., Sadeh, R., de Bie, P., & Ciechanover, A. J. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.025 · Cited by 55
BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients
Carvalho, D. D. D., Binato, R., Pereira, W. O., Leroy, J. M. G., Colassanti, M. D., Proto‐Siqueira, R., Bueno-da-Silva, A. E. B., Zago, M. A., Zanichelli, M. A., Abdelhay, E. S. F. W., et al. (2010) · Oncogene · doi:10.1038/onc.2010.409 · Cited by 54
The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma formation
Marchesi, I., Fiorentino, F. P., Rizzolio, F., Giordano, A., & Bagella, L. (2012) · Cell Cycle · doi:10.4161/cc.22025 · Cited by 52
NIPP1 maintains EZH2 phosphorylation and promoter occupancy at proliferation-related target genes
Minnebo, N., Görnemann, J., O’Connell, N., Dessel, N. V., Derua, R., Vermunt, M. W., Page, R., Beullens, M., Peti, W., Eynde, A. V., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1255 · Cited by 50
Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4
Lu, H., Sun, J., Wang, F., Feng, L., Ma, Y., Shen, Q., Jiang, Z., Sun, X., Wang, X., & Jin, H. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.293 · Cited by 50
Duan, Z., Zou, J. X., Yang, P. X., Wang, Y. Z., Borowsky, A. D., Gao, A. C., & Chen, H. (2012) · The Prostate · doi:10.1002/pros.22587 · Cited by 49
Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Fiskus, W. C., Rao, R., Balusu, R., Ganguly, S., Tao, J., Sotomayor, E. M., Mudunuru, U., Smith, J. E., Hembruff, S. L., Atadja, P. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0873 · Cited by 49
The polycomb group protein EZH2 regulates actin polymerization in human prostate cancer cells
Bryant, R. J., Winder, S. J., Cross, S. S., Hamdy, F. C., & Cunliffe, V. T. (2007) · The Prostate · doi:10.1002/pros.20705 · Cited by 47
Expression of EZH2 in renal cell carcinoma as a novel prognostic marker
Lee, H. W., & Choe, M. (2012) · Pathology International · doi:10.1111/pin.12001 · Cited by 44
The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma
Zhang, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1787 · Cited by 32
Mukhopadhyay, N. K., Kim, J., You, S., Morello, M., Hager, M. H., Huang, W.-C., Ramachandran, A., Yang, J., Cinar, B., Rubin, M. A., et al. (2013) · Oncogene · doi:10.1038/onc.2013.294 · Cited by 29
Wang, S., Zhu, Y., He, H., Liu, J., Xu, L., Zhang, H., Liu, H., Liu, W., Liu, Y., Pan, D., et al. (2013) · Cancer Science · doi:10.1111/cas.12132 · Cited by 26
Leseva, M. N., Santostefano, K. E., Rosenbluth, A., Hamazaki, T., & Terada, N. (2013) · Epigenetics · doi:10.4161/epi.25522 · Cited by 20
Cited by
Current state of melanoma diagnosis and treatment
Davis, L. E., Shalin, S. C., & Tackett, A. J. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1640032 · Cited by 922
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
Dotto, G. P., & Rustgi, A. K. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.004 · Cited by 319
Xu, M., Chen, X., Lin, K., Zeng, K., Liu, X., Pan, B., Xu, X., Xu, T., Hu, X., Sun, L., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0894-x · Cited by 298
Metadata
- Authors
- Yamaguchi, H., & Hung, M.-C.
- Venue
- Cancer Research and Treatment
- Publisher
- Korean Cancer Association
- Published
- 2014-07-15
- Volume
- 46
- Issue
- 3
- Pages
- 209-222
- ISSN
- 1598-2998 (ISSN-L)
- 2005-9256
- OpenAlex
- W2059058989
- Cited by
- 287
- References
- 171
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.